Dr. Strosberg on Quality of Life Findings for Lu-Dotatate in Patients with Midgut NETs

Jonathan R. Strosberg, MD
Published: Thursday, Jan 19, 2017



Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.
 
This preliminary analysis was part of the phase III NETTER-1 trial, which compared the efficacy of 177-Lu-Dotatate (Lutathera) with octreotide (Sandostatin LAR) in patients with advanced progressive disease. The analysis focused on the global health quality of life, which is an important quality of life endpoint in any type of cancer, Strosberg says.
 
Patients were provided with quality of life questionnaires containing both general cancer quality of life questions and specific gastrointestinal neuroendocrine tumor questions. What the analysis found was that, on average, more patients in the Lu-Dotatate arm of the study had improvement in their quality of life. Additionally, compared to the group receiving high-dose octreotide, fewer patients had a decline in their quality of life.
 
Overall, these results are very encouraging, Strosberg says.

<<< View more from the 2017 GI Cancers Symposium


Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.
 
This preliminary analysis was part of the phase III NETTER-1 trial, which compared the efficacy of 177-Lu-Dotatate (Lutathera) with octreotide (Sandostatin LAR) in patients with advanced progressive disease. The analysis focused on the global health quality of life, which is an important quality of life endpoint in any type of cancer, Strosberg says.
 
Patients were provided with quality of life questionnaires containing both general cancer quality of life questions and specific gastrointestinal neuroendocrine tumor questions. What the analysis found was that, on average, more patients in the Lu-Dotatate arm of the study had improvement in their quality of life. Additionally, compared to the group receiving high-dose octreotide, fewer patients had a decline in their quality of life.
 
Overall, these results are very encouraging, Strosberg says.

<<< View more from the 2017 GI Cancers Symposium



View Conference Coverage
OncLive SAP
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Articles
Blogs
Conference Coverage
OncLive TV
Peer Exchange
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
 
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.
 
x